Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer

6092 Background: Although laterally extended endopelvic resection (LEER) has been introduced to control the pelvic sidewall tumors, there is a lack of evidence about its efficacy and safety despite high skillful procedure, compared with the other treatments. Thus, we performed a prospective cohort study with historical comparison for four years. Methods: One gynecologic oncologist performed LEER consecutively for patients with the pelvic sidewall tumors between March 2014 and July 2018. We compared clinicopathologic characteristics and survival between patients who received primary LEER and with those treated with other treatments. Results: We enrolled 37 patients treated with LEER. Among them, 22 (59.5%) and 15 (40.5%) had recurrent and primary disease. Among perioperative outcomes, there was more estimated blood loss, and hospitalization was longer in recurrent disease and previous surgery (p < 0.05). In recurrent disease, previous progression-free survival < 8 months was related to poor recurrence-free survival after LEER (median, 5.4 vs. 10.2 months; p < 0.05). When LEER was applied for the first recurrence of cervical cancer, recurrence-free survival and overall survival after treatment seemed to be longer in LEER (n = 9) than in palliative chemotherapy (n = 27) without statistical significance (median, 12.2 vs. 4.7 months and 23.2 vs. 12.4 months; p = 0.13 and p = 0.63). In 15 patients with primary locally advanced cervical cancer, LEER after partial response to neoadjuvant chemotherapy showed longer progression-free survival than LEER after stable or progressive disease to neoadjuvant chemotherapy and primary radiotherapy (p = 0.012). After LEER, grade 3 and 4 complications developed in 15 (23.1%) and 2 (3.1%) patients. Conclusions: Compared with palliative chemotherapy, LEER followed by palliative chemotherapy may improve progression-free survival in patients with recurrent cervical cancer located in the pelvic sidewall. If possible, it is more effective to apply LEER without preceding palliative chemotherapy for recurrent cervical cancer located in the pelvic sidewall.

Download Full-text

A retrospective study of carboplatin and liposomal doxorubicin in patients with locally advanced or recurrent squamous cell carcinoma of the cervix.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e18021 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e18021-e18021

Author(s):

LEI Chang ◽

Zhongfu Yuan ◽

Wanjia Tian

Keyword(s):

Cervical Cancer ◽

Liposomal Doxorubicin ◽

Overall Response Rate ◽

Locally Advanced ◽

Drug Efficacy ◽

Efficacy And Safety ◽

Recurrent Cervical Cancer ◽

Starting Dose ◽

Recurrent Squamous Cell Carcinoma ◽

Duration Of Response

e18021 Background: The efficacy and safety of the combination of carboplatin and liposomal doxorubicin was tested in in patients with locally advanced or recurrent cervical cancer. Methods: The combination of carboplatin (area under the concentration curve AUC = 5) and liposomal doxorubicin (starting dose, 40 mg/m2) was administered intravenously every 28 days to 75 patients with locally advanced or recurrent cervical cancer to determine the drug efficacy and safety. Results: During the observation, all patients were received surgery or radiation before combination chemotherapy. 58 patients were assessable for response, and 12 patients were assessable for toxicity. During therapy, none patients required discontinuation of chemotherapy while only 2 patients needed dose reduction, because of side effect. The overall response rate was 77.3%, the median time to response was 8 weeks, the median duration of response was 24 weeks, and the median survival was 37 weeks. The most common adverse events with these patients included myelosuppression (69.0%), neutropenia (31.0%), anemia (23.0%), thrombocytopenia (21.0%) and neutropenic fever (11.0%). Conclusions: The combination of carboplatin and liposomal doxorubicin shows clinical efficacy and acceptable safety in patients with locally advanced or recurrent cervical carcinoma. It might provide a noval treatment for late stage cervical cancer.

Download Full-text

Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study

Oncology Research and Treatment ◽

10.1159/000510355 ◽

2020 ◽

Vol 43 (12) ◽

pp. 649-655

Author(s):

Xiaoping Xia ◽

Wenjing Jiang ◽

Wencai Qi ◽

Baoli Hong ◽

Weidong Zhao

Keyword(s):

Cervical Cancer ◽

Adverse Events ◽

Kinase Inhibitor ◽

Objective Response ◽

Progression Free Survival ◽

Complete Response ◽

Efficacy And Safety ◽

First Line ◽

Recurrent Cervical Cancer ◽

Line Chemotherapy

Purpose: As a small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), apatinib has shown a survival benefit in multiple solid tumors. This study aims to evaluate the efficacy and safety of apatinib in patients with metastatic, recurrent cervical cancer after failure of radiotherapy and first-line chemotherapy. Methods: A total of 42 patients between June 2018 and March 2019 were involved in this study. All patients orally received apatinib once daily in a 4-week cycle until disease progression or adverse events that prohibit further therapy. The primary endpoint was progression-free survival (PFS), the secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), health-related quality of life (HRQoL) and adverse events. Results: During a median follow-up of 13 months, 8 patients achieved a partial response and 24 cases achieved stable disease. None of them reported a complete response. The ORR and DCR were 19.0 and 76.2%, respectively. The median PFS was 6.0 months (95% CI 4.9–7.1), and the median OS was 12.0 months (95% CI 10.1–13.9). The global health score/HRQoL improved significantly following 3-cycle treatment (50.4 ± 12.5 vs. 60.1 ± 11.8; p < 0.01). The most frequent grade 3–4 adverse events were hand-foot syndrome, hypertension and fatigue. Conclusion: Apatinib should be an effective and tolerable treatment option for patients with metastatic, recurrent cervical cancer after failure of radiotherapy and first-line chemotherapy.

Download Full-text

Efficacy and safety of a 3D-printed applicator for vaginal brachytherapy in patients with central pelvic-recurrent cervical cancer after primary hysterectomy

Brachytherapy ◽

10.1016/j.brachy.2021.11.004 ◽

2021 ◽

Author(s):

Xue Qin ◽

Fuquan Zhang ◽

Xiaorong Hou ◽

Lang Yu ◽

Lihua Yu  ◽

...

Keyword(s):

Cervical Cancer ◽

Efficacy And Safety ◽

Recurrent Cervical Cancer ◽

3D Printed

Download Full-text

A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy

Case Medical Research ◽

10.31525/ct1-nct04150575 ◽

2019 ◽

Author(s):

Keyword(s):

Cervical Cancer ◽

Clinical Study ◽

Progressive Disease ◽

Advanced Cervical Cancer ◽

Efficacy And Safety ◽

First Line ◽

Standard Chemotherapy ◽

Line Standard

Download Full-text

Faculty of 1000 evaluation for Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717998895.793474496 ◽

2013 ◽

Author(s):

David Kushner

Keyword(s):

Cervical Cancer ◽

Phase Ii ◽

Survival Data ◽

Open Label ◽

Recurrent Cervical Cancer ◽

Open Label Study ◽

Label Study

Download Full-text

SURGERY FOR RESIDUAL DISEASE AFTER RADIOTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER

Problems in oncology ◽

10.37469/0507-3758-2019-65-5-721-725 ◽

2019 ◽

Vol 65 (5) ◽

pp. 721-725

Author(s):

Elmira Shakirova ◽

Andrey Panov ◽

Alevtina Akhmetzyanova ◽

Aliya Gafiullina ◽

L. Ibragimova ◽

...

Keyword(s):

Cervical Cancer ◽

Residual Disease ◽

Locally Advanced ◽

Residual Tumor ◽

Advanced Cervical Cancer ◽

Mri Imaging ◽

Recurrent Cervical Cancer ◽

Locally Advanced Cervical Cancer ◽

Visible Effect ◽

Adjuvant Hysterectomy

Aims: Chemoradiation (CRT) is the standard treatment for locally advanced cervical cancer (LACC). However part of the patients develop recurrence during the first year after treatment despite good visible effect at the first follow-up. The role of completion surgery after radiotherapy (RT) is still debated. A number of papers have showed that up to 60% of patients have residual tumor after CRT and RT. But such a surgery is not widely recommended because of increased morbidity of the treatment. The aim of this study was to assess the results of surgery after radiotherapy of LACC. Method: We retrospectively evaluated data on 86 patients with cervical cancer IB - IIIB stages (mostly stage IIB) who underwent surgery in different modalities after CRT and RT with good clinical response in our department in 2015-2018. Results: When small asymptomatic residual disease was detected early after radiotherapy radical hysterectomy was feasible in most of the cases. Patients with clinical manifestation of recurrence had very poor prognosis. Surgery of recurrent cervical cancer sufficiently deteriorates quality of life, even if possible. Conclusion: Thorough examination with adding MRI imaging after initial treatment of cervical cancer needed to identify patients who may benefit from adjuvant hysterectomy.

Download Full-text